Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Chan

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
World Journal of Clinical Oncology|February 21, 2012
Colon cancer in a patient with underlying aplastic anemia: A clinical challengeHilda Wong, Pierre Chan, Thomas Yau
World Journal of Gastroenterology|November 26, 2008
Evolution of systemic therapy of advanced hepatocellular carcinomaThomas Yau, Pierre Chan, Richard Epstein, et al.
Expert Opinion on Pharmacotherapy|August 17, 2010
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenibThomas Yau, Roberta Pang, Pierre Chan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2009
Management of advanced hepatocellular carcinoma in the era of targeted therapyThomas Yau, Pierre Chan, Richard Epstein, et al.
World Journal of Surgical Oncology|April 24, 2008
Intramuscular recurrence in a hepatocellular carcinoma patient with indolent disease courseThomas Yau, Hilda Wong, Pierre Chan, et al.
Clinical Colorectal Cancer|April 10, 2010
Transient carcinoembryonic antigen elevations during adjuvant chemotherapy for colorectal cancer reflect the burden of residual micrometastatic diseaseThomas Yau, Hilda Wong, Pierre Chan, et al.
Cancer|July 15, 2010
Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinomaThomas Yau, Pierre Chan, Roberta Pang, et al.
Expert Opinion on Investigational Drugs|April 9, 2010
Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for useVictoria P Y Tan, Pierre Chan, Ivan F N Hung, et al.
Cancer|October 15, 2008
A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trialsThomas Yau, Tzy Jyun Yao, Pierre Chan, et al.
The Oncologist|September 3, 2011
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenibThomas Yau, T J Yao, Pierre Chan, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
World Journal of Clinical Oncology|February 21, 2012
Colon cancer in a patient with underlying aplastic anemia: A clinical challengeHilda Wong, Pierre Chan, Thomas Yau
World Journal of Gastroenterology|November 26, 2008
Evolution of systemic therapy of advanced hepatocellular carcinomaThomas Yau, Pierre Chan, Richard Epstein, et al.
Expert Opinion on Pharmacotherapy|August 17, 2010
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenibThomas Yau, Roberta Pang, Pierre Chan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2009
Management of advanced hepatocellular carcinoma in the era of targeted therapyThomas Yau, Pierre Chan, Richard Epstein, et al.
World Journal of Surgical Oncology|April 24, 2008
Intramuscular recurrence in a hepatocellular carcinoma patient with indolent disease courseThomas Yau, Hilda Wong, Pierre Chan, et al.
Clinical Colorectal Cancer|April 10, 2010
Transient carcinoembryonic antigen elevations during adjuvant chemotherapy for colorectal cancer reflect the burden of residual micrometastatic diseaseThomas Yau, Hilda Wong, Pierre Chan, et al.
Cancer|July 15, 2010
Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinomaThomas Yau, Pierre Chan, Roberta Pang, et al.
Expert Opinion on Investigational Drugs|April 9, 2010
Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for useVictoria P Y Tan, Pierre Chan, Ivan F N Hung, et al.
Cancer|October 15, 2008
A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trialsThomas Yau, Tzy Jyun Yao, Pierre Chan, et al.
The Oncologist|September 3, 2011
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenibThomas Yau, T J Yao, Pierre Chan, et al.
Pageof 4